Orphazyme A/S
CSE:ORPHA
Orphazyme A/S
CSE:ORPHA
Price:
850
DKK
1.19%
Market Closed
Market Cap:
kr34m
Relative Value
There is not enough data to reliably calculate the relative value of ORPHA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ORPHA
Relative Value
Base Case
Not Available
Multiples Across Competitors
ORPHA Competitors Multiples
Orphazyme A/S Competitors
Orphazyme A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Orphazyme A/S
CSE:ORPHA
|
34m DKK | 0 | -3 | -1.3 | -1.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD | 6.6 | 168.5 | 16.3 | 23.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD | 5.6 | 26.6 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD | 6.5 | 23.3 | 15.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD | 10.4 | 33 | 24.3 | 25.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.3 | 15.6 | 17.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD | 3.9 | 20.2 | 13.5 | 16.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 14 | 32.9 | 56 | 57.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
